TYRO3 and urinary bladder neoplasm: Nevertheless, ligand-independent activation has also been reported for strong TYRO3 expression,6 and we show here that TYRO3 is N-glycosylated in bladder tumours, which might lead to its ligand-independent activation in the presence of galectin, in a process similar to that described for N-glysosylated vascular endothelial growth factor receptor 2, which is activated by galectin-1 in the absence of ligand.28